Compound Information | SONAR Target prediction |
Name: | CARBAMAZEPINE |
Unique Identifier: | SPE01500159 |
MolClass: | Checkout models in ver1.5 and ver1.0 |
Molecular Formula: | |
Molecular Weight: | 224.173 g/mol |
X log p: | 20.464 (online calculus) |
Lipinksi Failures | 1 |
TPSA | 20.31 |
Hydrogen Bond Donor Count: | 0 |
Hydrogen Bond Acceptors Count: | 3 |
Rotatable Bond Count: | 1 |
Canonical Smiles: | NC(=O)N1c2ccccc2C=Cc2ccccc12 |
Source: | synthetic |
Therapeutics: | analgesic, anticonvulsant |
Generic_name: | Carbamazepine |
Chemical_iupac_name: | 5H-dibenz[b,f]azepine-5-carboxamide |
Drug_type: | Approved Drug |
Kegg_compound_id: | C06868 |
Drugbank_id: | APRD00337 |
Melting_point: | 190.2 oC |
H2o_solubility: | 17.7 mg/L |
Logp: | 2.69 |
Cas_registry_number: | 298-46-4 |
Mass_spectrum: | http://webbook.nist.gov/cgi/cbook.cgi?Spec=C298464&Index=0&Type=Mass&Large=on |
Drug_category: | Analgesics; Antimanic Agents; Anticonvulsants; ATC:N03AF01 |
Indication: | For the treatment of epilepsy and pain associated with true trigeminal neuralgia. |
Pharmacology: | Carbamazepine, an anticonvulsant structurally similar to tricyclic antidepressants, is used to treat partial seizures, tonic-clonic seizures, pain of neurologic origin such as trigeminal neuralgia, and psychiatric disorders including manic-depressive illness and aggression due to dementia. |
Mechanism_of_action: | Carbamazepine inhibits sustained repetitive firing by blocking use-dependent sodium channels. Pain relief is believed to be associated with blockade of synaptic transmission in the trigeminal nucleus and seizure control with reduction of post-tetanic potentiation of synaptic transmission in the spinal cord. Carbamazepine also possesses anticholinergic, central antidiuretic, antiarrhythmic, muscle relaxant, antidepressant (possibly through blockade of norepinephrine release), sedative, and neuromuscular-blocking properties. |
Organisms_affected: | Humans and other mammals |